Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) will likely be announcing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($0.04) per share and revenue of $1.4320 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:30 AM ET.
Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The company had revenue of $1.26 million for the quarter, compared to analyst estimates of $1.38 million. On average, analysts expect Lucid Diagnostics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.
Lucid Diagnostics Price Performance
Shares of LUCD opened at $0.96 on Tuesday. Lucid Diagnostics has a one year low of $0.86 and a one year high of $1.63. The company’s fifty day moving average price is $1.00 and its 200 day moving average price is $1.13. The company has a market capitalization of $195.17 million, a PE ratio of -2.04 and a beta of 1.08.
Insider Buying and Selling at Lucid Diagnostics
Institutional Investors Weigh In On Lucid Diagnostics
Several large investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in Lucid Diagnostics by 9.6% during the third quarter. Vanguard Group Inc. now owns 4,523,997 shares of the company’s stock worth $4,569,000 after buying an additional 396,719 shares during the last quarter. Masters Capital Management LLC grew its position in Lucid Diagnostics by 46.6% during the 3rd quarter. Masters Capital Management LLC now owns 3,999,273 shares of the company’s stock worth $4,039,000 after acquiring an additional 1,272,000 shares during the last quarter. Two Seas Capital LP bought a new position in Lucid Diagnostics in the 3rd quarter valued at $3,030,000. Geode Capital Management LLC boosted its stake in Lucid Diagnostics by 21.1% in the fourth quarter. Geode Capital Management LLC now owns 2,026,827 shares of the company’s stock worth $2,209,000 after purchasing an additional 352,654 shares in the last quarter. Finally, Alyeska Investment Group L.P. boosted its stake in Lucid Diagnostics by 87.3% in the third quarter. Alyeska Investment Group L.P. now owns 1,383,116 shares of the company’s stock worth $1,397,000 after purchasing an additional 644,839 shares in the last quarter. Institutional investors own 74.01% of the company’s stock.
Analysts Set New Price Targets
LUCD has been the subject of several research analyst reports. Ascendiant Capital Markets boosted their price objective on Lucid Diagnostics from $9.00 to $9.25 and gave the stock a “buy” rating in a research report on Monday, June 8th. Maxim Group decreased their price target on shares of Lucid Diagnostics from $3.00 to $2.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Weiss Ratings upgraded shares of Lucid Diagnostics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 4th. BTIG Research reaffirmed a “buy” rating and set a $2.50 price objective on shares of Lucid Diagnostics in a research report on Friday, May 15th. Finally, Wall Street Zen cut shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $4.19.
Read Our Latest Report on Lucid Diagnostics
About Lucid Diagnostics
Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.
Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.
Featured Stories
- Five stocks we like better than Lucid Diagnostics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
